Non-steroidal anti-inflammatory drugs
| | | | | | |
Warfarin (2.5)
|
12.9 (1637)
|
2.8 (9)
|
12.1
|
3.9
|
<.001
|
Increased bleeding risk
|
ASA, low dose (11.7)
|
13.6 (1558)
|
5.8 (88)
|
12.5
|
7.4
|
<.001
|
Increased bleeding risk
|
SSRI (1.5)
|
12.5 (1602)
|
22.0 (44)
|
11.8
|
19.5
|
.001
|
Increased bleeding risk
|
Glucocorticoids (1.3)
|
12.7 (1625)
|
12.6 (21)
|
11.9
|
13.0
|
.672
|
Increased bleeding risk
|
ACE inhibitors (3.8)
|
12.9 (1614)
|
6.5 (32)
|
12.0
|
7.8
|
.007
|
Diminished effect, renal impairment, hyperkalemia
|
AT II antagonists (9.2)
|
12.8 (1508)
|
11.5 (138)
|
11.8
|
12.8
|
.326
|
Diminished effect, renal impairment, hyperkalemia
|
Other antihypertensives (18.8)b
|
13.3 (1397)
|
10.2 (249)
|
11.8
|
12.1
|
.693
|
Diminished effect
|
Opioids
| | | | | | |
CNS depressants (4.9)c
|
2.9 (359)
|
18.1 (116)
|
2.9
|
17.5
|
<.001
|
CNS depression, respiratory depression, falls
|
Paracetamol
| | | | | | |
Warfarin (2.5)
|
13.6 (1719)
|
7.1 (23)
|
12.5
|
9.5
|
.154
|
Increased bleeding risk
|